HematologyNews.net

Hematology Xagena

A phase-I study for patients with chronic lymphocytic leukaemia has shown promising results. Chronic lymphocytic leukaemia ( CLL ) is the most common leukemia in adults in the Western world and is dia ...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...


The results of phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera were presented at the 50th Annual Meeting of the American Society of Clinical Oncology ( ASCO ). ...


Phosphatidylinositol-3-kinase delta ( PI3Kδ ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 ...


The monoclonal anti-CD20 antibody Rituximab ( MabThera, Rituxan ), combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreate ...


Acute lymphoblastic leukemia ( ALL ) is a rare type of blood cancer which is mainly treated by intensive chemotherapy. If the disease is resistant to initial treatment or reoccurs ( relapse ) the cha ...


Patients with relapsed chronic lymphocytic leukemia ( CLL ) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with accep ...


Immobilization of the lower leg is associated with venous thromboembolism ( VTE ). Low molecular weight Heparin ( LMWH ) is an anticoagulant treatment which might be used in adult patients with lower- ...


The combination of lenalidomide ( Revlimid ) and Rituximab ( Rituxan ) has shown synergistic activity in chronic lymphocytic leukemia ( CLL ) preclinical models. In a CLL Research Consortium phase I ...


Updated interim results of a phase 2 study ( Study 102 ) evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase ( Syk ), for the treatment of patients with relapsed chronic ly ...


Early results of a randomized phase III GITMO/FIL study comparing CHOP-R vs. R-HDS + ASCT as primary treatment in 134 FL pts, aged less than or equal to 60 yrs with aaIPI greater than 1/IIL score grea ...


The results from PANORAMA-1 ( PANobinostat ORAl in Multiple MyelomA ) trial were presented at ASCO meeting, showing a 37% improvement in progression-free survival ( PFS ) when using the investigationa ...


The FDA ( Food and Drug Administration ) has approved a Supplemental Biologic License Application ( sBLA ) for the use of Arzerra ( Ofatumumab ), a CD20-directed cytolytic monoclonal antibody, in comb ...


A group of researchers at the Institute for Research in Immunology and Cancer ( IRIC ) of Université de Montréal discovered a promising new approach to treating leukemia by disarming a gene that is re ...


The Food and Drug Administration ( FDA ) has expanded the approved use of Imbruvica ( Ibrutinib ) for chronic lymphocytic leukemia ( CLL ) patients who have received at least one previous therapy.Chro ...